Enveric Biosciences
ENVB
Market cap $3.26M

0.3650 USD

-0.0320

8.06%

At close Nov 15, 4:00 PM EST

After hours

0.3776

+0.0126

3.45%

1 day

-8.06%

5 days

-22.34%

1 month

-13.71%

3 months

-24.43%

6 months

-53.68%

Year to date

-71.03%

1 year

-74.48%

5 years

-99.76%

10 years

-99.99%

About: Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Employees: 26

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

6% more capital invested

Capital invested by funds: $307K [Q2] → $326K (+$18.9K) [Q3]

1.19% more ownership

Funds ownership: 6.53% [Q2] → 7.72% (+1.19%) [Q3]

6% less funds holding

Funds holding: 17 [Q2] → 16 (-1) [Q3]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ENVB.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ENVB published over the past 30 days

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. “The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge.

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-licensing the Company's EVM201 program, including drug candidate EB-002. Pursuant to the terms of licensing agreement,.

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office. The U.

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced positive results for preclinical safety and pharmacology studies, which evaluated off-target interactions of its lead drug candidate, EB-003, and confirmed selective activity with desired serotonergic neurorec.

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company's identification of EB-003 as its lead development candidate based on preclinical data suggesting the compound exhibits promising anxiolytic and anti-depre.

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that research highlighting the Company's lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,N-Dimethyltryptamine.

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024. During the presentation, Dr. Tucker will discuss the development of novel neuroplastogen.

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology (“Aries”), a developer of encapsulation technologies, today announced that Patent No. 12,059,393 was issued on August 13, 2024, to Enveric's wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”). We believe the newly issued intellectual property stren.

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The second quarter of 2024 was marked by the prioritization of EB-003 as our lead development candidate. This strat.

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?

Enveric Biosciences (NASDAQ: ENVB ) stock is heading higher on Tuesday alongside heavy pre-market trading of the biotechnology company's shares. This comes with more than 13 million shares of ENVB stock changing hands as of this writing.

Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?

See News Rankings

Charts implemented using Lightweight Charts™